PRKDC and neoplasm: Olaparib combined with ML216 significantly decreased the expressions of pBRCA1 (Ser1524), Rad50, Mre11, RPA70, and Rad51 in A549 tumor xenografts after irradiation (P < 0.05) (Figure 5F and Supplementary Figure S5C), while olaparib combined with ML216 increased the phosphorylation of DNA-PKcs (Ser2056) in A549 tumor xenografts after irradiation (P < 0.05) (Figure 5F and Supplementary Figure S5C).